Parthenon LLC Sells 3,137 Shares of Kenvue Inc. (NYSE:KVUE)

Parthenon LLC lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,266 shares of the company’s stock after selling 3,137 shares during the period. Parthenon LLC’s holdings in Kenvue were worth $3,214,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Clearstead Advisors LLC purchased a new position in Kenvue during the third quarter worth $25,000. Planned Solutions Inc. purchased a new stake in shares of Kenvue during the fourth quarter valued at $27,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Kenvue during the third quarter valued at $28,000. Venturi Wealth Management LLC purchased a new stake in shares of Kenvue during the third quarter valued at $28,000. Finally, Cullen Frost Bankers Inc. purchased a new stake in shares of Kenvue during the third quarter valued at $29,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. William Blair initiated coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Finally, Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Trading Down 1.3 %

Shares of KVUE traded down $0.24 during mid-day trading on Tuesday, hitting $18.82. 26,741,112 shares of the company traded hands, compared to its average volume of 16,772,949. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a 50 day moving average of $19.84 and a 200 day moving average of $20.14.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Equities analysts predict that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be given a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.25%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.